Syntheses of FDA approved HIV protease inhibitors

A. K. Ghosh*, G. Bilcer, G. Schiltz

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    138 Scopus citations

    Abstract

    The treatment of HIV and AIDS was revolutionized by the introduction of peptidomimetic aspartyl protease inhibitors. One of the major limitations of this type of therapy is that higher therapeutic doses are necessary because of the presence of 'peptide-like' features in the drugs. Therefore, adequate supplies and cost effective syntheses of these drugs are of utmost importance. To date, there are six protease inhibitors approved by the United States Food and Drug Administration (FDA) for the treatment of HIV and AIDS. This review focuses on the published syntheses of currently FDA approved HIV protease inhibitor drugs, their isosteres and ligands.

    Original languageEnglish (US)
    Pages (from-to)2203-2229
    Number of pages27
    JournalSynthesis
    Issue number15
    DOIs
    StatePublished - 2001

    Keywords

    • HIV
    • Inhibitor
    • Isostere
    • Protease
    • Synthesis

    ASJC Scopus subject areas

    • Catalysis
    • Organic Chemistry

    Fingerprint

    Dive into the research topics of 'Syntheses of FDA approved HIV protease inhibitors'. Together they form a unique fingerprint.

    Cite this